Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tandem Diabetes Care (TNDM)

Tandem Diabetes Care (TNDM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,324,851
  • Shares Outstanding, K 67,802
  • Annual Sales, $ 940,200 K
  • Annual Income, $ -96,030 K
  • EBIT $ -196 M
  • EBITDA $ -180 M
  • 60-Month Beta 1.68
  • Price/Sales 1.30
  • Price/Cash Flow N/A
  • Price/Book 9.60

Options Overview Details

View History
  • Implied Volatility 95.71% (+3.54%)
  • Historical Volatility 41.40%
  • IV Percentile 86%
  • IV Rank 59.90%
  • IV High 125.46% on 09/11/25
  • IV Low 51.27% on 06/12/25
  • Expected Move (DTE 9) 3.15 (16.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 74
  • Volume Avg (30-Day) 221
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 6,919
  • Open Int (30-Day) 7,252
  • Expected Range 16.52 to 22.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.05
  • Number of Estimates 8
  • High Estimate 0.05
  • Low Estimate -0.28
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +88.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.50 +6.27%
on 02/11/26
22.14 -11.18%
on 01/12/26
-2.04 (-9.40%)
since 01/09/26
3-Month
16.95 +15.99%
on 11/14/25
24.50 -19.76%
on 12/16/25
+2.14 (+12.21%)
since 11/11/25
52-Week
9.98 +96.99%
on 08/07/25
35.12 -44.02%
on 02/25/25
-13.86 (-41.35%)
since 02/11/25

Most Recent Stories

More News
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

NEW YORK , Feb. 7, 2026 /PRNewswire/ --

TNDM : 19.66 (+0.61%)
1 Small-Cap Stock with Exciting Potential and 2 Facing Headwinds

1 Small-Cap Stock with Exciting Potential and 2 Facing Headwinds

TNDM : 19.66 (+0.61%)
IRTC : 152.11 (-0.07%)
AHCO : 10.54 (-0.94%)
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

NEW YORK , Jan. 31, 2026 /PRNewswire/ --

TNDM : 19.66 (+0.61%)
3 Stocks Under $50 That Fall Short

3 Stocks Under $50 That Fall Short

MCFT : 24.42 (+1.08%)
TNDM : 19.66 (+0.61%)
EBC : 21.52 (-0.23%)
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

NEW YORK , Jan. 26, 2026 /PRNewswire/ -- 

TNDM : 19.66 (+0.61%)
3 Reasons to Avoid TNDM and 1 Stock to Buy Instead

3 Reasons to Avoid TNDM and 1 Stock to Buy Instead

TNDM : 19.66 (+0.61%)
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

NEW YORK , Jan. 21, 2026 /PRNewswire/ --

TNDM : 19.66 (+0.61%)
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

NEW YORK , Jan. 16, 2026 /PRNewswire/ --

TNDM : 19.66 (+0.61%)
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2025 results after the financial markets close on...

TNDM : 19.66 (+0.61%)
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM

NEW YORK , Dec. 30, 2025 /PRNewswire/ --

TNDM : 19.66 (+0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tandem Diabetes Care, Inc. designs, develops and markets products for people with insulin-dependent diabetes. The company's flagship product, the t:slim X2 Insulin Delivery System, or t:slim X2, is based on its proprietary technology platform. Per the company, t:slim X2 is the smallest durable insulin...

See More

Key Turning Points

3rd Resistance Point 21.64
2nd Resistance Point 20.78
1st Resistance Point 20.22
Last Price 19.66
1st Support Level 18.80
2nd Support Level 17.94
3rd Support Level 17.38

See More

52-Week High 35.12
Fibonacci 61.8% 25.52
Fibonacci 50% 22.55
Last Price 19.66
Fibonacci 38.2% 19.58
52-Week Low 9.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar